A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis

NCT06921759 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

206

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Hand and Foot Dermatitis

Interventions

DRUG: Lebrikizumab
DRUG: Placebo

Sponsor

Eli Lilly and Company